Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors

HE Shannon, FP Bymaster, DO Calligaro, B Greenwood, CH Mitch, BD Sawyer, JS Ward, DT Wong, PH Olesen and MJ Sheardown

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.

Xanomeline [3(3-hexyloxy-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1- methylpyridine] has been evaluated as a muscarinic receptor agonist. In vitro, xanomeline had high affinity for muscarinic receptors in brain homogenates, but had substantially less or no affinity for a number of other neurotransmitter receptors and uptake sites. In cells stably expressing genetic m1 receptors, xanomeline increased phospholipid hydrolysis in CHO, BHK and A9 L cells to 100, 72 and 55% of the nonselective agonist carbachol. In isolated tissues, xanomeline had high affinity for M1 receptors in the rabbit vas deferens (IC50 = 0.006 nM), low affinity for M2 receptors in guinea pig atria (EC50 = 3 microM), was a weak partial agonist in guinea pig ileum and was neither an agonist nor antagonist in guinea pig bladder. In vivo, xanomeline increased striatal levels of dopamine metabolites, presumably by acting at M1 heteroreceptors on dopamine neurons to increase dopamine release. In contrast, xanomeline had only a relatively small effect on acetylcholine levels in brain, indicating that it is devoid of actions at muscarinic autoreceptors. In the gastrointestinal tract, xanomeline inhibited small intestinal and colonic motility, but increased small intestinal transmural potential difference. In contrast to the nonselective muscarinic agonist oxotremorine, xanomeline did not produce salivation, tremor nor hypothermia; it did, however, increase heart rate. The present data are consistent with the interpretation that xanomeline is a novel muscarinic receptor agonist with functional selectivity for M1 muscarinic receptors both in vitro and in vivo.

Volume 269, Issue 1, pp. 271-281, 04/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				A. Shekhar, W. Z. Potter, J. Lightfoot, J. Lienemann, S. Dube, C. Mallinckrodt, F. P. Bymaster, D. L. McKinzie, and C. C. Felder Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia Am J Psychiatry, August 1, 2008; 165(8): 1033 - 1039. [Abstract] [Full Text] [PDF]

				H. Salah-Uddin, D. R. Thomas, C. H. Davies, J. J. Hagan, M. D. Wood, J. M. Watson, and R. A. J. Challiss Pharmacological Assessment of M1 Muscarinic Acetylcholine Receptor-Gq/11 Protein Coupling in Membranes Prepared from Postmortem Human Brain Tissue J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 869 - 874. [Abstract] [Full Text] [PDF]

				K. C. De Lorme, M. K.O. Grant, M. J. Noetzel, S. B. Polson, and E. E. El-Fakahany Long-Term Changes in the Muscarinic M1 Receptor Induced by Instantaneous Formation of Wash-Resistant Xanomeline-Receptor Complex J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 868 - 876. [Abstract] [Full Text] [PDF]

				E. Machova, J. Jakubik, E. E. El-Fakahany, and V. Dolezal Wash-Resistantly Bound Xanomeline Inhibits Acetylcholine Release by Persistent Activation of Presynaptic M2 and M4 Muscarinic Receptors in Rat Brain J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 316 - 323. [Abstract] [Full Text] [PDF]

				J. Jakubik, E. E. El-Fakahany, and V. Dolezal Differences in Kinetics of Xanomeline Binding and Selectivity of Activation of G Proteins at M1 and M2 Muscarinic Acetylcholine Receptors Mol. Pharmacol., August 1, 2006; 70(2): 656 - 666. [Abstract] [Full Text] [PDF]

				M. K. O. Grant and E. E. El-Fakahany Persistent Binding and Functional Antagonism by Xanomeline at the Muscarinic M5 Receptor J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 313 - 319. [Abstract] [Full Text] [PDF]

				C. K. Jones, E. L. Eberle, D. B. Shaw, D. L. McKinzie, and H. E. Shannon Pharmacologic Interactions between the Muscarinic Cholinergic and Dopaminergic Systems in the Modulation of Prepulse Inhibition in Rats J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1055 - 1063. [Abstract] [Full Text] [PDF]

				K. J. Stanhope, N. R. Mirza, M. J. Bickerdike, J. L. Bright, N. R. Harrington, M. B. Hesselink, G. A. Kennett, S. Lightowler, M. J. Sheardown, R. Syed, et al. The Muscarinic Receptor Agonist Xanomeline Has an Antipsychotic-Like Profile in the Rat J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 782 - 792. [Abstract] [Full Text] [PDF]

				A. Christopoulos, M. K. O. Grant, N. Ayoubzadeh, O. N. Kim, P. Sauerberg, L. Jeppesen, and E. E. El-Fakahany Synthesis and Pharmacological Evaluation of Dimeric Muscarinic Acetylcholine Receptor Agonists J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1260 - 1268. [Abstract] [Full Text] [PDF]

				H. Hirose, I. Aoki, T. Kimura, T. Fujikawa, T. Numazawa, K. Sasaki, A. Sato, T. Hasegawa, M. Nishikibe, M. Mitsuya, et al. Pharmacological Properties of (2R)-N-[1-(6-Aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2- hydroxy-2-phenylacetamide: A Novel Muscarinic Antagonist with M2-Sparing Antagonistic Activity J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 790 - 797. [Abstract] [Full Text]

				P. W. Stengel and M. L. Cohen Low-Affinity M2 Receptor Binding State Mediates Mouse Atrial Bradycardia: Comparative Effects of Carbamylcholine and the M1 Receptor Agonists Sabcomeline and Xanomeline J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 818 - 824. [Abstract] [Full Text]

				A. C. Bartolomeo, H. Morris, J. J. Buccafusco, N. Kille, S. Rosenzweig-Lipson, M. G. Husbands, A. L. Sabb, M. Abou-Gharbia, J. A. Moyer, and C. A. Boast The Preclinical Pharmacological Profile of WAY-132983, a Potent M1 Preferring Agonist J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 584 - 596. [Abstract] [Full Text]

				H. E. Shannon, J. C. Hart, F. P. Bymaster, D. O. Calligaro, N. W. DeLapp, C. H. Mitch, J. S. Ward, A. Fink-Jensen, P. Sauerberg, L. Jeppesen, et al. Muscarinic Receptor Agonists, Like Dopamine Receptor Antagonist Antipsychotics, Inhibit Conditioned Avoidance Response in Rats J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 901 - 907. [Abstract] [Full Text]

				B. Ahren, P. Sauerberg, and C. Thomsen Increased insulin secretion and normalization of glucose tolerance by cholinergic agonism in high fat-fed mice Am J Physiol Endocrinol Metab, July 1, 1999; 277(1): E93 - E102. [Abstract] [Full Text] [PDF]

				A. Christopoulos, A. M. Parsons, and E. E. El-Fakahany Pharmacological Analysis of the Novel Mode of Interaction between Xanomeline and the M1 Muscarinic Acetylcholine Receptor J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1220 - 1228. [Abstract] [Full Text]

				A. Christopoulos, T. L. Pierce, J. L. Sorman, and E. E. El-Fakahany On the Unique Binding and Activating Properties of Xanomeline at the M1 Muscarinic Acetylcholine Receptor Mol. Pharmacol., June 1, 1998; 53(6): 1120 - 1130. [Abstract] [Full Text]

				J. M. Loudon, S. M. Bromidge, F. Brown, M. S. G. Clark, J. P. Hatcher, J. Hawkins, G. J. Riley, G. Noy, and B. S. Orlek SB 202026: A Novel Muscarinic Partial Agonist with Functional Selectivity for M1 Receptors J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1059 - 1068. [Abstract] [Full Text]

				J. Jakubík and E. E. El-Fakahany Positive Cooperativity of Acetylcholine and Other Agonists with Allosteric Ligands on Muscarinic Acetylcholine Receptors Mol. Pharmacol., July 1, 1997; 52(1): 172 - 179. [Abstract] [Full Text]

				H. E. Shannon, M. J. Sheardown, F. P. Bymaster, D. O. Calligaro, N. W. Delapp, J. Gidda, C. H. Mitch, B. D. Sawyer, P. W. Stengel, J. S. Ward, et al. Pharmacology of Butylthio[2.2.2] (LY297802/NNC11-1053): A Novel Analgesic with Mixed Muscarinic Receptor Agonist and Antagonist Activity J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 884 - 894. [Abstract] [Full Text]

				A. Medina, N. Bodick, A. L. Goldberger, M. M. Mahon, and L. A. Lipsitz Effects of Central Muscarinic-1 Receptor Stimulation on Blood Pressure Regulation Hypertension, March 1, 1997; 29(3): 828 - 834. [Abstract] [Full Text]